Carsten Schmitz-Peiffer

A/Prof Carsten Schmitz-Peiffer is the Head of the Insulin Signalling Group at the Garvan Institute, focusing on investigating lipid-induced insulin resistance, a critical aspect of Type 2 Diabetes. His research has emphasized the significance of protein kinase C (PKC) and ceramide in the metabolic interplay between adipose tissue and the liver. Utilizing cutting-edge proteomics and lipidomics, he delves into the underlying mechanisms. Carsten collaborates with pharmaceutical and biotech companies, actively working on developing innovative PKC inhibitors for diabetes treatment through advanced screening methods and fragment-based drug design. His educational background includes an honors degree in Natural Sciences (Biochemistry) from the University of Cambridge and a PhD in Biochemistry from the University of Bristol. Carsten holds the position of Associate Professor at the University of New South Wales, having previously served as a Senior Research Fellow at the Garvan Institute of Medical Research and a Senior Lecturer at the University of New South Wales. He also contributes to grant review committees and has editorial roles in scientific journals.